<DOC>
	<DOCNO>NCT01980966</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety MHAA4549A healthy volunteer influenza challenge model . Subjects intranasally oculated challenge virus randomly assign receive intravenous dose either MHAA4549A placebo . In stage 5 cohort , subject randomly assign receive dos MHAA4549A placebo Tamiflu ( oseltamivir ) orally twice daily 5 day . All subject cohort may take Tamiflu twice daily Day 7 Day 11 .</brief_summary>
	<brief_title>A Study MHAA4549A Healthy Volunteers Influenza Challenge Model</brief_title>
	<detailed_description />
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>In good health history major medical condition medical history , physical examination routine laboratory test Male subject woman childbearing potential must use effective contraception define protocol , start entry quarantine continue Day 120 followup visit Serosuitable challenge virus Women pregnant within 6 month prior study , breastfeed within 3 month prior study , positive pregnancy test point study Any history evidence clinically significant cardiovascular , gastrointestinal , endocrinological , haematological , hepatic , immunological , metabolic , urological , neurological , psychiatric , renal , and/or major disease malignancy , judge CI Abnormal pulmonary function evidence clinically significant abnormality spirometry History asthma , COPD , pulmonary hypertension , reactive airway disease , chronic lung disease etiology . A history childhood asthma age 12 acceptable provide subject asymptomatic without treatment . History suggestive respiratory infection within 14 day prior admission unit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>